SCHEMBL1133036

SCHEMBL1133036

CN(/N=C/c1ccc(O)cc1O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.64
MEN1 O00255 6/20 0.64
KMT2A Q03164 6/20 0.64
LMNA P02545 4/20 0.64
PAX8 Q06710 1/20 0.64
SMN1; SMN2 Q16637 3/20 0.54
HCRTR1 O43613 1/20 0.54
TDP1 Q9NUW8 3/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
GAA P10253 2/20 0.51
MAPK1 P28482 2/20 0.51
HTT P42858 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
ALDH1A1 P00352 1/20 0.49
KDM4E B2RXH2 2/20 0.48
HSP90AA1 P07900 1/20 0.47
POLB P06746 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133038 1.00 MAPT (0.64) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL8416037 0.88 MAPT (0.65) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL8416040 0.88 MAPT (0.65) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL1132254 0.84 POLB (0.66) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL1132255 0.84 POLB (0.66) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL1132529 0.84 MAPT (0.60) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL1132528 0.84 MAPT (0.60) MAPTMEN1KMT2ALMNAPAX8
SCHEMBL5632591 0.81 MAPT (0.78) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5632589 0.81 MAPT (0.78) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL11353829 0.78 MAPT (0.61) MAPTMEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US claimed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US claimed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP claimed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO claimed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO claimed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 EP claimed
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 EP disclosed
EP-0597128-B1 ESTER POLYMER, PRODUCTION THEREOF, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR MADE THEREFROM IDEMITSU KOSAN CO (JP) 1999-09-15 EP disclosed
US-5561017-A A CHARGE TRANSFER COMPOUND AND/OR BINDER COMPRISING A POLYESTER OR -CARBONATE OF AN ARYL HYDRAZONE MONOMER; ELECTROGRAPHY; PLATES; WEAR RESISTANCE IDEMITSU KOSAN CO., LTD. (JP) 1996-10-01 US disclosed
US-5506331-A POLYESTER OR POLYCARBONATE HAVING HYDRAZONE STRUCTURE IN REPEATING UNITS, USABLE AS CHARGE TRANSPORT MATERIAL OR BINDER RESIN IN CHARGE TRANSPORT LAYER IDEMITSU KOSAN CO., LTD. (JP) 1996-04-09 US disclosed
EP-0597128-A1 ESTER POLYMER, PRODUCTION THEREOF, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR MADE THEREFROM IDEMITSU KOSAN COMPANY LIMITED (JP) 1994-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB MAPT 149/4885MEN1 3413/4885KMT2A 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.